Navigation Links
AMT Starts Development LPLChip(TM) With Progenika
Date:10/29/2009

s release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
2. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
3. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
4. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
5. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
6. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
7. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
10. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
11. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 EHE International, the recognized leader in preventive ... today announced that David Abrams M.D . in ... preventive care center. Through David Abrams M.D ., EHE ... have greater access to EHE,s preventive care programs to help ... to add Dr. Abrams M.D. to its growing private provider ...
(Date:9/16/2014)... Ariz. , Sept. 16, 2014 Surgeons ... describe in a case report the first successful ... in a 13- year-old boy with failing Fontan circulation ... When he was 3 years old, the patient received ... known as functional single ventricle. "The Fontan operation is ...
(Date:9/16/2014)... , Sept. 16, 2014 The ... Directors Institute has simultaneously released the NAMCP Medical ... Medical Diagnostics Dossier Template © , which provide ... formats for either medical devices or diagnostics that ... of each of these technology types (instead of ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2
... MINNEAPOLIS and HUDIKSVALL, Sweden, Oct. 6 Nonin ... manufacturing center, formerly MedAir AB, has changed its ... operations to better serve Nonin Medical,s European customers ... and service Nonin,s European capnography products, Nonin Medical ...
... Scripts (Nasdaq: ESRX ) has completed the ... a new independent, nonprofit charitable organization with the mission ... Americans and working families. Michael Holmes, ... new national organization, which has its headquarters in St. ...
Cached Medicine Technology:Nonin Medical, Inc. Announces Capnography Division Name Change; Expands Swedish Manufacturing Facility to Become Full-Franchise European Sales, Distribution and Service Center 2Express Scripts Completes Spinoff of Rx Outreach 2
(Date:9/16/2014)... September 15, 2014 For patients with locally advanced ... ablative radiation (SABR) may be a promising treatment ... may not otherwise be an option, according to ... Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. , Surgery ... with pancreatic ductal adenocarcinoma (PDA), the most common ...
(Date:9/16/2014)... Discussion abstracts to be presented at the ESMO 2014 ... 2014 at 12:00 (CEST) to give you a first ... medical oncology Congress, under the leading theme Precision Medicine ... where genuinely targeted therapy is now possible for an ... are all working towards a common goal --improved patient ...
(Date:9/16/2014)... 2014 Fresh shiitake mushrooms are ... potassium. They are second-most consumed mushroom worldwide, for ... healing and health properties. , In addition to ... stimulate and strengthen the immune system and fight ... including beta glucans . These medicinal properties ...
(Date:9/16/2014)... 16, 2014 Brightree® , ... and billing software solutions for the post-acute care ... latest release of Brightree HME , serving ... providers as well as home infusion pharmacies. The ... (PARs), electronic purchasing, document management and electronic eligibility ...
(Date:9/16/2014)... Transparency Market Research, a U.S. - based ... market is expected to report an approximate value of ... Market (By Product Type - Skin Whitening/ Lightening and ... Masks and Others (fade creams, pore strips and toners)- ... 2013 – 2019,’ is now available for sale on ...
Breaking Medicine News(10 mins):Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:ESMO 2014 Congress Preview 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3Health News:Brightree Announces Availability of Latest Release 2Health News:Brightree Announces Availability of Latest Release 3Health News:Brightree Announces Availability of Latest Release 4Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
... syndrome, by which 15% of Americans were suffered, was ... help, there's often little left// to do but to ... gas, flatulence make their lives miserable, limiting some of ... most basic of treatments is lifestyle modification instead of ...
... whether if new drugs and technologies are cost effective or not//. ... ... But British Medical Journal doctors complained that NICE has carried ... NHS resources better. ,NICE has published about 86 sets of guidance and recommendations ...
... the students and junior medical doctors of the Medical ... Hospitals have decided to not to run the outpatient ... protesting doctors have however promised not to cause any ... run a ‘parallel OPD’s’ for the benefit of patents. ...
... The soft green substance inside the body of a lobster ... delicacy and by may others as a waste//, unhealthy product. ... warning-advising people against eating too much of lobster tomalley. ... innards that serve as a liver and pancreas for lobster, ...
... medicos strike in India, the government on Sunday night proposed ... quota in central educational institutes// but the students and doctors ... calling a bandh in Delhi on May 31. ... with Federal Minister Oscar Fernandes who followed it up with ...
... the quota issue has been put on the national agenda ... many other more pressing problems. // ,Sam Pitroda ... criterion for selecting students for institutions of higher education. But ... of Technology (IITs) is not feasible. Already, the existing IITs ...
Cached Medicine News:Health News:Silence Puts Comfort For Digestive Syndrome 2Health News:Agitating Doctors Call For Two Day Shut Down Of OPD’ 2Health News:Quota System: Diverting Attention From The Real Problem 2Health News:Quota System: Diverting Attention From The Real Problem 3Health News:Quota System: Diverting Attention From The Real Problem 4
... Battery Powered Orthopedic Systems., ,The PowerPro® ... to the Hall® Surgical line of powered ... the first and only software controlled battery ... is a full-function orthopedic power system specifically ...
... Brasseler USAs Large Bone Power System is ... new technological advancements. The truly innovative design ... pack, which is comprised of the battery, ... contains only mechanical components, which provides a ...
... is a type I collagen implant designed ... or loss of meniscus tissue, typically through ... purpose of the CMI is to assist ... a more vigorous lifestyle, while forestalling or ...
... OBIs proprietary PolyGraft® material technology which ... that is both biologically friendly and ... of polylactide-co-glycolide, calcium sulfate and polyglycolide ... fabricated into products such as granules, ...
Medicine Products: